Saturn Biosciences
Turning Immune System on Cancer
(Website under construction)
- Saturn Biosciences is focused on developing SAT012 (fka AS-1409), a clinical stage asset, to address the huge market of oncology patients not responding to checkpoint inhibitors.
- SAT012 (huBC1-huIL12) is a novel tumor-targeted immunocytokine fusion protein.
- SAT012 has completed a successful Phase 1 as a monotherapy.
- The mechanism of action of IL12 encapsulated in SAT012 by its “tumor-only” targeting makes it an ideal candidate to switch non-responders to anti-PD1/PDL1 therapies or therapeutic cancer vaccines to responders.
- Saturn is preparing to initiate Phase 1b/2 POC study with an anti-PD1/PDL1 antibody in an immuno-responsive cancer (e.g., NSCLC).